MTOR and PTEN hamartoma tumor syndrome: Isolated case reports have shown some benefit from AKT-mTOR pathway inhibition using sirolimus in open-label trials in PHTS patients (Iacobas et al., 2011; Marsh et al., 2008), whereas other reports have shown more limited efficacy (Schmid et al., 2014).